SCVIi001-A

iPSC Line

Provider

External iPSC Databases

General iPSC Information

• Liu L et al. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy. Stem cell research. 2021 May;53:102279.
• Mondéjar-Parreño G et al. Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome. Stem cell research. 2021 Jul;54:102402.
• Caudal A et al. Generation of human induced pluripotent stem cell lines carrying heterozygous PLN mutation from dilated cardiomyopathy patients. Stem cell research. 2022 Aug;63:102855.
• Zeng W et al. Generation of two induced pluripotent stem cell lines from spinal muscular atrophy type 1 patients carrying no functional copies of SMN1 gene. Stem cell research. 2023 Jun;69:103095.
• Zhu W et al. Generation of two induced pluripotent stem cell lines from patients with Down syndrome. Stem cell research. 2023 Oct;72:103204.
• Karakan MÇ et al. Geometry and length control of 3D engineered heart tissues using direct laser writing. Lab on a chip. 2024 Mar 12;24(6):1685-1701.
• Kathirgamanathan Abiramee et al. Preventing Atrial Fibrillation in Hypertrophic Cardiomyopathy using Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs). Undergraduate Research in Natural and Clinical Science and Technology Journal. 2024-03-15.
• Ribeiro M et al. Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation. Human cell. 2024 Jul;37(4):1205-1214.
• Ewoldt JK et al. Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling. Science advances. 2024 Oct 18;10(42):eadi6927.
• Jager Joanna et al. Patient-derived induced pluripotent stem cells to study non-canonical splicing variants associated with Hypertrophic Cardiomyopathy. Stem Cell Research. 2024-12-00.

General